Filing Details
BridgeBio Pharma, Inc. (NASDAQ:BBIO) filed a Form 8-K with the Securities and Exchange Commission on August 17, 2026, disclosing a material event.
8k filedNASDAQ:BBIO
BridgeBio Pharma, Inc. (BBIO) Reports Material Event to SEC
BridgeBio Pharma, Inc. (NASDAQ:BBIO) filed a Form 8-K with the Securities and Exchange Commission on August 17, 2026, disclosing a material event.
At publication ·
What changed
BridgeBio Pharma, Inc. (NASDAQ:BBIO) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- BridgeBio Pharma filed a Form 8-K with the SEC on August 17, 2026, disclosing a material event that shareholders should be aware of, though the specific nature of the event is not detailed in this article.
- The company's stock was trading at $79.89 with a market capitalization of $14.1 billion at the time of the filing.
- Form 8-K filings are used to report material events such as leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance that occur between regular quarterly or annual reports.
Market Context
BridgeBio Pharma, Inc.'s stock currently trades at $79.89 with a market capitalization of $14.1B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for BridgeBio Pharma, Inc.'s stock.
All SEC filings for BridgeBio Pharma, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View BBIO Stock Page
Frequently Asked Questions
Where can I read BBIO's SEC filings?
Browse all filings on our BBIO SEC filings page.
What types of SEC filings does BridgeBio Pharma, Inc. file?
Public companies like BridgeBio Pharma, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
